ES3005482T3 - A complex of a glucopyranosyl derivative and preparation method and use thereof - Google Patents
A complex of a glucopyranosyl derivative and preparation method and use thereof Download PDFInfo
- Publication number
- ES3005482T3 ES3005482T3 ES16868062T ES16868062T ES3005482T3 ES 3005482 T3 ES3005482 T3 ES 3005482T3 ES 16868062 T ES16868062 T ES 16868062T ES 16868062 T ES16868062 T ES 16868062T ES 3005482 T3 ES3005482 T3 ES 3005482T3
- Authority
- ES
- Spain
- Prior art keywords
- complex
- inhibitor
- crystal
- crystalline form
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H9/00—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical
- C07H9/02—Compounds containing a hetero ring sharing at least two hetero atoms with a saccharide radical the hetero ring containing only oxygen as ring hetero atoms
- C07H9/04—Cyclic acetals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H1/00—Processes for the preparation of sugar derivatives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/04—Carbocyclic radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyrrole Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510851466 | 2015-11-27 | ||
| PCT/CN2016/107543 WO2017088839A1 (en) | 2015-11-27 | 2016-11-28 | A complex of a glucopyranosyl derivative and preparation method and use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES3005482T3 true ES3005482T3 (en) | 2025-03-14 |
Family
ID=58763019
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES16868062T Active ES3005482T3 (en) | 2015-11-27 | 2016-11-28 | A complex of a glucopyranosyl derivative and preparation method and use thereof |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US10555930B2 (enExample) |
| EP (1) | EP3371199B1 (enExample) |
| JP (1) | JP6916180B2 (enExample) |
| CN (1) | CN106810582B (enExample) |
| AU (1) | AU2016360634B2 (enExample) |
| CA (1) | CA3005920C (enExample) |
| ES (1) | ES3005482T3 (enExample) |
| WO (1) | WO2017088839A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107778336B (zh) * | 2016-08-24 | 2022-09-27 | 宜昌东阳光长江药业股份有限公司 | 吡喃葡萄糖基衍生物的结晶形式 |
| CN108239123B (zh) * | 2016-12-27 | 2021-08-27 | 宜昌东阳光长江药业股份有限公司 | 吡喃葡萄糖基衍生物的共晶、制备方法和应用 |
| IL280880B2 (en) | 2018-08-27 | 2025-04-01 | Regeneron Pharma | Using Raman Spectroscopy in Downstream Purification |
| CN110407891A (zh) * | 2019-07-31 | 2019-11-05 | 扬子江药业集团北京海燕药业有限公司 | 一种sglt-2抑制剂中间体的精制方法 |
| CN114796250A (zh) * | 2021-01-27 | 2022-07-29 | 宜昌东阳光长江药业股份有限公司 | 一种含有吡喃葡萄糖基衍生物的药物组合物 |
| WO2022204907A1 (en) * | 2021-03-30 | 2022-10-06 | Sunshine Lake Pharma Co., Ltd. | Method for preparing cocrystal of l-pyroglutamic acid and glucopyranosyl derivative |
| CN115141235B (zh) * | 2021-03-30 | 2024-08-09 | 宜昌东阳光长江药业股份有限公司 | 吡喃葡萄糖基衍生物的l-焦谷氨酸共晶的制备方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7919598B2 (en) * | 2006-06-28 | 2011-04-05 | Bristol-Myers Squibb Company | Crystal structures of SGLT2 inhibitors and processes for preparing same |
| WO2015027963A1 (zh) * | 2013-09-02 | 2015-03-05 | 四川海思科制药有限公司 | 芳环类衍生物、其药物组合物及其应用 |
| ES2605886T3 (es) * | 2013-09-27 | 2017-03-16 | Sunshine Lake Pharma Co., Ltd. | Derivados de glucopiranosilo y sus usos en medicina |
| WO2016173425A1 (en) * | 2015-04-30 | 2016-11-03 | Sunshine Lake Pharma Co., Ltd. | A glucopyranosyl derivative and preparation method and uses thereof |
-
2016
- 2016-11-28 CA CA3005920A patent/CA3005920C/en active Active
- 2016-11-28 US US15/778,220 patent/US10555930B2/en active Active
- 2016-11-28 AU AU2016360634A patent/AU2016360634B2/en active Active
- 2016-11-28 CN CN201611070532.8A patent/CN106810582B/zh active Active
- 2016-11-28 JP JP2018527236A patent/JP6916180B2/ja active Active
- 2016-11-28 EP EP16868062.7A patent/EP3371199B1/en active Active
- 2016-11-28 WO PCT/CN2016/107543 patent/WO2017088839A1/en not_active Ceased
- 2016-11-28 ES ES16868062T patent/ES3005482T3/es active Active
Also Published As
| Publication number | Publication date |
|---|---|
| HK1254667A1 (en) | 2019-07-26 |
| JP6916180B2 (ja) | 2021-08-11 |
| CA3005920C (en) | 2023-08-22 |
| CA3005920A1 (en) | 2017-06-01 |
| CN106810582A (zh) | 2017-06-09 |
| CN106810582B (zh) | 2019-12-31 |
| EP3371199B1 (en) | 2024-12-25 |
| US10555930B2 (en) | 2020-02-11 |
| AU2016360634B2 (en) | 2020-05-21 |
| AU2016360634A1 (en) | 2018-06-07 |
| EP3371199A1 (en) | 2018-09-12 |
| EP3371199A4 (en) | 2019-06-12 |
| WO2017088839A1 (en) | 2017-06-01 |
| US20180344689A1 (en) | 2018-12-06 |
| JP2018535237A (ja) | 2018-11-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES3005482T3 (en) | A complex of a glucopyranosyl derivative and preparation method and use thereof | |
| CN107698569B (zh) | 作为jak抑制剂的联吡唑衍生物 | |
| KR101971387B1 (ko) | Ask1 억제제의 고체 형태 | |
| WO2022100623A1 (zh) | 氮取代杂环噻吩类化合物及其用途 | |
| CN108239123B (zh) | 吡喃葡萄糖基衍生物的共晶、制备方法和应用 | |
| CN106674294B (zh) | 吡喃葡萄糖基衍生物的结晶形式 | |
| CN104053439A (zh) | 1-(5,6-二氯-1h-苯并[d]咪唑-2-基)-1h-吡唑-4-羧酸的葡甲胺盐制剂 | |
| TWI822666B (zh) | Janus激酶抑制劑之結晶型 | |
| US9957282B2 (en) | Crystalline forms of quinolone analogs and their salts | |
| JP2018537486A (ja) | キノロン類似体及びその塩の結晶形 | |
| CN107778336B (zh) | 吡喃葡萄糖基衍生物的结晶形式 | |
| EP4635947A2 (en) | Crystal form of glucopyranosyl derivative and use thereof | |
| CN118206518A (zh) | 吡喃葡萄糖基衍生物的共晶及其用途 | |
| HK1254667B (en) | A complex of a glucopyranosyl derivative and preparation method and use thereof | |
| TW202102487A (zh) | N-(5-((4-乙基哌𠯤-1-基)甲基)吡啶-2-基)-5-氟-4-(3-異丙基-2-甲基-2h-吲唑-5-基)嘧啶-2-胺及其鹽的結晶與非晶型以及其製備方法與醫療用途 | |
| US20250074892A1 (en) | Carbonyl bridged heterocyclic compound, and composition and application thereof | |
| CN106674245B (zh) | 吡喃葡萄糖基衍生物的制备及医药上的应用 | |
| CN118206517A (zh) | 吡喃葡萄糖基衍生物的共晶及其用途 | |
| CN118206516A (zh) | 吡喃葡萄糖基衍生物的共晶及其用途 | |
| CN116437917A (zh) | Atx抑制剂氘代衍生物及其应用 | |
| HK40115319A (en) | Carbonyl bridged heterocyclic compound, and composition and application thereof | |
| KR20170115315A (ko) | 신규한 헤테로사이클릭 유도체 및 이들의 용도 | |
| WO2017128042A1 (zh) | 咪唑酮类化合物的晶型、其制备方法、药物组合物和用途 |